Alle Storys
Folgen
Keine Story von Schering Deutschland GmbH mehr verpassen.

Schering Deutschland GmbH

euro adhoc: Schering AG
other
PTK/ZK CONFIRM 1 Phase III Study Shows Positive Drug Effects in Metastatic Colorectal Cancer - Filing Now Anticipated for Early 2007

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
21.03.2005
Schering AG announced today that the analysis of progression free
survival (PFS) as assessed by central radiology review in the CONFIRM
1 trial with the investigational drug PTK/ZK based on information
obtained after trading hours on March 18, 2005 did not achieve
statistical significance. However, a separate pre-planned analysis of
progression-free survival as assessed by the investigators achieved
statistical significance.
Further analysis of the data including more detailed evaluations of
subpopulations are ongoing to fully assess the potential benefit of
PTK/ZK.
Based on a review of the CONFIRM 1 results, an independent data
monitoring board recommended the phase III clinical trial program to
continue to allow analysis of overall survival endpoints. This is
expected in the second half of 2006.
Another ongoing phase III trial, CONFIRM 2, compares the PTK/ZK
combination regimen to FOLFOX-4 alone in patients with metastatic
colorectal cancer who have progressed after irinotecan-based
chemotherapy. An interim analysis is planned in mid 2005 and final
overall survival data are expected in mid 2006.
Filing for approval with the U.S. Food and Drug Administration (FDA)
and the European Medicines Agency (EMEA) is now anticipated in early
2007.
end of announcement                    euro adhoc 21.03.2005 05:30:00 

Further inquiry note:

Oliver Renner
Head Corporate Business Communication
Tel.: +49 (0)30 468 12431
Fax: +49 (0)30 468 16646
E-Mail: oliver.renner@schering.de

Branche: Pharmaceuticals
ISIN: DE0007172009
WKN: 717200
Index: DAX, Prime Standard, CDAX, HDAX, Prime All Share
Börsen: Baden-Württembergische Wertpapierbörse / regulated dealing
SWX Swiss Exchange / regulated dealing
Niedersächsische Börse zu Hannover / regulated dealing
New York / ADR
Berliner Wertpapierbörse / official dealing
Hamburger Wertpapierbörse / official dealing
Frankfurter Wertpapierbörse / official dealing
Börse Düsseldorf / official dealing
Bayerische Börse / official dealing
Bremer Wertpapierbörse (BWB) / official dealing

Weitere Storys: Schering Deutschland GmbH
Weitere Storys: Schering Deutschland GmbH